Guidance, NICE advice and quality standards in development | Guidance

Showing 241 to 250 of 300

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]	Technology appraisal guidance	14 May 2026
Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]	Technology appraisal guidance	TBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance	TBC
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]	Technology appraisal guidance	17 December 2025
Sotatercept for treating pulmonary arterial hypertension [ID6163]	Technology appraisal guidance	15 October 2025
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091	Technology appraisal guidance	TBC